PubMed Health⌕ Search

Biomedical subjects

Hermann A M Mucke

Publications and source records attributed to Hermann A M Mucke.

13 recordsLinked to original sources
PubMed2007

New ocular therapeutics: a view from the patenting perspective.

This feature article provides an overview of the newest therapeutic developments for ocular diseases, based on patents and patent applications that were published in the 12-month period from November 2005 to October 2006. In contrast to peer-reviewed literature covering breakthroughs in basic science research, the patenting perspective discloses the intentions of the pharmaceutical industry for imminent drug development. Selected documents describing drug delivery, dry eye syndrome, ocular infections and lesions, glaucoma and age-related macular degeneration are discussed. The role of RNA interference, which is of particular interest in ophthalmology research, is also highlighted.

Drug Industry↗
PubMed2006

Cardiovascular and renal developments: patent highlights January to June 2006.

Failure of the cardiovascular system is the main reason for mortality in industrialized countries, and is a major cause of chronic morbidity. As most of the numerous ways in which it can fail will manifest in the second half of life and are exacerbated by old age, this situation is not likely to change in the near future unless fundamentally new ways of treating or preventing hypertension, atherosclerosis, myocardial infarction, chronic heart failure and cardiac arrhythmia are found. This prospect keeps the pharmaceutical industry on a constant, intense search for new therapeutic targets, new drugs, and new ways to identify such targets and drugs, as well as monitoring patient responses to drugs. This summary highlights the most interesting developments seen in cardiovascular and renal patents (other than those claiming formulations or combinations of known drugs) published during the first half of 2006.

Animals↗
PubMed2005

[State of the art management of BPSD in dementia].

OBJECTIVE: To obtain a cross-sectional overview of therapeutic practice concerning non-cognitive, behavioral signs and symptoms of dementia (BPSD) in Germany, Austria, and Switzerland. METHOD: We selected 24 psychiatrists (8 from each country) for a questionnaire-based survey with 28 detailed practical questions. RESULTS: Attitudes and preferences were in line with the state of the art as documented in the literature, with the exception of the fact that 30 % of the physicians favored a too brief therapeutic trial with selective serotonin re-uptake inhibitors (SSRIs) for agitation. According to the international literature the preferred treatment of psychotic symptoms in Parkinsons's disease is also a little bit different. Modern atypical antipsychotics, and particularly risperidone, were highly favored for agitation, delirium, psychotic symptoms, and rage outbursts; benzodiazepines (oxazepam and lorazepam), and to an extent also low-potency conventional antipsychotics, were favored only for brief ad hoc medication courses. Anxiety and depressive symptoms were preferentially treated with SSRI, with the exception of short-term therapy of generalized anxiety where benzodiazepines were favored. Benzodiazepines and zolpidem were favored for insomnia without pronounced nocturnal agitation. CONCLUSION: Psychiatrists at memory clinics in German-speaking Europe have therapeutic attitudes and practices that are consistent with the current state of the art.

Alzheimer Disease↗
PubMed2004

Zotepine for behavioural and psychological symptoms in dementia: an open-label study.

OBJECTIVE: To provide initial information on the safety and efficacy of the atypical antipsychotic zotepine in the treatment of behavioural and psychological symptoms of dementia (BPSD). METHODS: This was an open-label, single-centre field study. Twenty-four patients with BPSD associated with Alzheimer's disease (n=12) or other forms of dementia (n=12) were included. During the 8-week observation period, the patients received zotepine (Nipolept) [12.5-150 mg/day] for the psychotic components of BPSD; no other treatment interventions for BPSD were allowed. At baseline, day 28 and day 56, patients were evaluated using the Clinical Global Impressions (CGI) scale; the Mini-Mental State Examination (MMSE), the Syndrome Brief Test (SKT) and the Age Concentration Test (AKT) to assess cognition; and the Neuropsychiatric Inventory (NPI) and the Cohen-Mansfield Agitation Inventory (CMAI) to assess BPSD. General adverse effects and, more specifically, the emergence of extrapyramidal symptoms were also assessed. RESULTS: There was no change from baseline to day 56 in the CGI score and the caregiver burden (as indicated by the caregiver-related section of the NPI). There was also no change in cognition (as assessed by the MMSE, SKT and AKT). The neuropsychiatric symptom score according to part 1 of the NPI (especially key psychotic symptoms, aggression and disinhibition) and the CMAI scores improved by 36% and 15%, respectively, between baseline and the end of the study in a highly statistically significant fashion. No significant differences in treatment response or adverse effect profile were noted between the 12 patients with Alzheimer's disease and the 12 patients with other types of dementia. Zotepine was well tolerated, with tiredness and sedation (five and four cases, respectively) being the most frequent complaints. No clinically significant emergence of extrapyramidal symptoms was seen. CONCLUSIONS: Zotepine appears to be well tolerated and effective in treating BPSD, consistent with the performance of other atypical antipsychotic drugs in this condition. Larger, controlled studies are warranted.

Aged↗
PubMed2003

Rotigotine Schwarz Pharma.

Schwarz Pharma AG, under license from Aderis Pharmaceuticals Inc, is developing rotigotine CDS, a once-daily transdermal patch formulation of rotigotine, which is a naphthol-derived selective D(2) dopamine agonist, for the potential treatment of Parkinson's disease and restless legs syndrome.

Animals↗
PubMed2002

Frovatriptan Vernalis.

Vanguard (now Vernalis) has developed frovatriptan, a selective 5-HT1B/1D partial agonist licensed from GlaxoSmithKline as a potential treatment for migraine [188478], [194382], [377863].

Carbazoles↗